Skip to Content

Nanosonics Ltd NNCSF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Nanosonics is a single-product company, and its trophon device provides automated high-level disinfection, or HLD, of ultrasound probes used in semicritical procedures. The patented technology uses low temperature sonically activated hydrogen peroxide mist that is suitable for the sensitive probe. Automated HLD is increasingly being adopted as the standard of care globally as it is superior in preventing cross-infection across patients. Nanosonics’s revenue stream comprises capital sales of trophon units and ongoing consumables sales. As at June 2020, there were 23,720 trophon units installed globally. Market penetration rates range from 77% in Australia and New Zealand, approximately 52% in the United States to low-single-digit penetration in EMEA and elsewhere in Asia-Pacific.

Contact
14 Mars Road, Lane Cove
Sydney, NSW, 2066, Australia
T +61 280631600
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings
Fiscal Year End Jun 30, 2021
Stock Type
Employees 311